COPD clinical trials

Explore recruiting copd clinical trials.

Recruiting copd studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

COPD trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO)

Sweden, Romania, Spain, Italy, Germany, Poland +11 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

The effect of Broncho-Vaxom on the COPD exacerbations in terms of lung function, lung mechanics, immune state, body composition, quality of life and physical activity.

Hungary

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 2a, open-label, two-part study to evaluate the mechanism of action of itepekimab (anti-IL-33 mAb) on airway inflammation in patients with chronic obstructive pulmonary disease (COPD)

Belgium, Germany, Netherlands, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Czechia, Germany, Poland, Hungary, Spain, France +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter, randomized, double-blind, parallel group, placebo-controlled study of the efficacy and safety of early depemokimab initiation as add-on treatment in COPD patients with type 2 inflammation.

Germany, Belgium, Netherlands, Denmark, Spain, Greece +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (TITANIA)

Poland, Germany, Italy, France, Romania, Greece

Therapeutic confirmatory (Phase III) EU CTIS Study details

COPD trials by city

COPD in Toronto COPD in Vancouver COPD in Montreal COPD in Calgary COPD in Edmonton COPD in Ottawa COPD in Winnipeg COPD in Quebec City COPD in Hamilton COPD in Kitchener COPD in London COPD in Halifax COPD in New York COPD in Los Angeles COPD in Chicago COPD in Houston

Other conditions

Dementia Depression Anxiety Bipolar disorder Schizophrenia PTSD OCD ADHD Insomnia Postpartum depression Alcohol use disorder Substance use disorder Asthma Long COVID Cystic fibrosis Pulmonary fibrosis Sleep apnea Chronic cough Crohn's disease Ulcerative colitis Irritable bowel syndrome Celiac disease GERD Eosinophilic esophagitis